Continuous or Intermittent Pyrotinib for HER2-positive Advanced Breast Cancer

This is a prospective, randomised, controlled, multicentre study to evaluate the efficacy and safety of continuous versus intermittent pyrotinib therapy in patients with human epidermal growth factor receptor (HER2)-positive advanced breast cancer.

Trial Details

NCT ID
NCT07180082
Phase
PHASE2
Sponsor
Wenjin Yin
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • Pyrotinib
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Age≥18 years old
  • Pathologically confirmed advanced or locally advanced breast cancer not amenable to curative surgery
  • Pathologically confirmed HER2+ at least once for either primary or metastatic lesion
  • Previously treated with any number of lines for advanced disease and eligible for a pyrotinib-containing regimen at the discretion of physician

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →